Approximately 170 million people are infected with hepatitis C virus (HCV), with the majority developing chronic infection (1) . With no vaccine currently available, the only approved treatment consists of a combination of alpha interferon (IFN-␣) and ribavirin (RBV), a guanosine nucleoside analog. IFN-␣ monotherapy has limited success, with only 16 to 20% of genotype 1-infected patients achieving a sustained virological response (SVR). However, the addition of RBV doubled response rates to 35 to 40%. Current treatment regimens including pegylated IFN and RBV achieve SVR rates of 54 to 56% in genotype 1-infected patients, while SVR rates of 70 to 80% are achieved in genotype 2-or 3-infected patients. The patient response is divided into three categories: SVR, end-of-treatment response and relapse, and nonresponse. Little is known about factors that influence the treatment response, although various host and viral factors have been implicated. For instance, genotype 1 infections are more difficult to treat than those of other genotypes. Additionally, male gender, AfricanAmerican race, advanced age, fibrosis, obesity, human immunodeficiency virus coinfection, and low RBV serum concentrations have been negatively correlated with treatment success (3, 14, 26, 27, 34, 35) .
Although RBV clearly plays a role in the HCV treatment response, the antiviral mechanism remains controversial. There are many proposed mechanisms of action for RBV (6, 10, 37, 63) . First, RBV directly inhibits the viral RNA-dependent RNA polymerase through incorporation of RBV triphosphate (RTP) (6, 37, 63) . Incorporation of RTP inhibits chain elongation and causes termination. Second, RBV inhibits the activity of inosine monophosphate dehydrogenase (IMPDH) (36, 43, 58) , the host enzyme responsible for de novo synthesis of GTP. The monophosphorylated form of RBV, RMP, binds to the substrate pocket of IMPDH, thereby inhibiting the enzyme and reducing host nucleotide pools, which are required for viral replication. Third, RBV is a viral mutagen (7, 8, 62) . For poliovirus, the incorporation of RTP into the viral RNA causes transition mutations (8) . RNA viruses have high replicative error rates, and incorporation of RTP can increase the error rate to the point of error catastrophe. Fourth, RBV treatment can inhibit mRNA capping, potentially affecting viral replication either indirectly for HCV or directly for viruses with capped RNA genomes or mRNAs (19) . Fifth, RBV shifts the immune response to a beneficial Th1-cell-mediated response (46, 60) . Although there is evidence to support each of the proposed mechanisms, the antiviral mechanism of RBV for HCV remains uncertain.
Factors that influence the treatment response are not completely understood. Unlike the case for human immunodeficiency virus, no clear drug resistance mutations that can account for treatment failure have been identified for HCV (2, 12, 23, 28, 57, 65) . Therefore, the HCV treatment response may be influenced more by host factors than by viral factors. Our previous work sought to determine whether RBV-resistant (RBV r ) HCV replicon-containing cells could be generated (49) . Whereas some low-level resistance occurred through mutations in the replicon, the majority of resistance occurred through changes in the cell line. These RBV r cells demonstrated a RBV uptake defect.
RBV is imported into cells through host nucleoside trans-porters (25) , which are divided into two categories, equilibrative and concentrative (31) . The equilibrative nucleoside transporters include ENT1, ENT2, ENT3, and ENT4, which are carrier proteins that mediate facilitated bidirectional diffusion of nucleosides across the cell membrane. The concentrative transporters CNT1, CNT2, and CNT3 are able to transport nucleosides against a concentration gradient by coupling transport to the inwardly directed sodium gradient. The transporters differ in tissue distributions and substrate preferences. ENT1 is generally considered ubiquitous and has broad substrate selectivity (9, 31) . Although ENT2 and CNT3 are also broadly selective, ENT2 is expressed predominantly in skeletal muscle, while CNT3 is found largely in the mammary gland, pancreas, bone marrow, and trachea (9, 31, 47) . Both the concentrative and equilibrative transporters are capable of importing synthetic nucleosides (13, 29, 33, 42, 54, 70) in addition to natural nucleosides. Therefore, nucleoside transporters are important clinically, since many nucleoside analogs are currently in use for the treatment of cancer and viral infections. Although the anti-HCV mechanism of RBV is controversial, at least four of the five proposed mechanisms require RBV import into the cell. We have therefore focused our efforts toward examining RBV uptake and the effect of uptake on antiviral efficacy.
In this study, we sought to understand RBV uptake and cell-based mechanisms of RBV resistance. We were able to generate RBV r cells in all cell lines tested, and we demonstrated that resistance is likely achieved by reduced ENT1-mediated uptake. We found that, in the presence of RBV, RBV r cells facilitate increased growth of poliovirus, a model RNA virus with known sensitivity to RBV, compared to RBVsensitive (RBV s ) cells. Additionally, by inhibiting equilibrative transport, the RBV r phenotype was mimicked in RBV s cells, for both RBV uptake and poliovirus growth. Our results suggest that the level of RBV uptake may affect the HCV treatment response, either through natural equilibrative transport variance in patients or through acquired resistance.
MATERIALS AND METHODS
Cell lines. All cell lines were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine or calf serum and 100 U of penicillinstreptomycin/ml. The Cured 4 cell line has been previously described (49) . Briefly, RBV r replicon-containing Huh-7 cells were generated by repeated passage in RBV, and the cells were cured of the replicon by IFN treatment. The Huh-7 (human hepatoma), 293 (human embryonic kidney), HeLa (human cervical carcinoma), HepG2 (human liver; a kind gift from M. Gale), PH5CH8 (human primary liver; a kind gift from M. Gale), and MCF7 (human breast adenocarcinoma) cell lines are used in this study.
Poliovirus infections. Mahoney serotype 1 poliovirus was generated as previously described from a single plaque following transfection of the viral cDNA clone (52) , and high-titer stocks were generated as previously described (30) . All plaque assays were performed at 37°C. For the Cured 4, Huh-7, HeLa, HepG2, and PH5CH8 cells, virus was added at 70 to 100 PFU/monolayer in 60-mm tissue culture plates. The MCF7 cells were infected with 10-fold more virus (700 PFU/plate) due to decreased permissivity. Following a 30-min incubation period, virus was aspirated, and an agar overlay, with or without 400 M RBV (Sigma), was added. After 48 h of incubation, the cells were stained with crystal violet to visualize plaques.
Generation of RBV r cell lines and RBV resistance assay. RBV r cell lines were generated as previously described (49) . Briefly, cells were initially passaged in medium containing 100 M RBV for approximately 4 weeks. The concentration of RBV was subsequently increased in 2-week intervals until a concentration of 400 M was achieved. The cells were maintained in medium containing 400 M RBV for approximately 2 to 4 weeks, and the level of RBV resistance was determined as previously described (49) , by splitting cells every 1 to 3 days for 10 days and staining with crystal violet to visualize cellular viability.
Uptake assays. Cells were plated the day prior to the assay on 35- . Following a 30-min incubation period at 37°C, the cells were washed twice with ice-cold phosphate-buffered saline to terminate uptake. The cells were then trypsinized and collected via centrifugation. Cell pellets were resuspended in 100 l of cold lysis buffer (10 mM Tris at pH 8, 10 mM NaCl, 1.5 mM MgCl 2 , and 0.1% NP-40). Cell debris was removed by centrifugation, and 40 l of the supernatant was quantified by scintillation counting. Cell number was determined by trypan blue counting of trypsinized cells from an additional plate. Uptake values were determined by multiplying the counts per minute per cell by 2.5 to account for the amount of lysate counted in the scintillator. The hypoxanthine uptake assays were performed in the same manner, except that the incubation period was reduced to 5 min to minimize the amount of [ 3 H]hypoxanthine (Moravek, Brea, CA) metabolized and exported out of the cell.
Transfections and inhibitor assays. Transfections were performed using 2 g of plasmid DNA (pcDNA 3.1, pENT1, pCNT1, pCNT2, pCNT3 [kindly provided by K. Giacomini, University of California-San Francisco], or pLacZ) and Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. pLacZ-transfected cells were stained as previously described (50) with 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal) at 24 h posttransfection to monitor transfection efficiency, which ranged from 40 to 90%, based on the number of blue cells observed under the microscope. For uptake assays involving the inhibitor nitrobenzylmercaptopurine riboside (NBMPR; Sigma), cells were pretreated at the appropriate concentration for 15 min. For those involving phloridzin (Sigma), 15 min of pretreatment was not required; therefore, the pretreatment incubation period was shortened to 5 min. Following inhibitor pretreatment, uptake assays were preformed as described above, with the exception that the incubation period was reduced to 5 min.
Real-time RT-PCR and immunoblot analysis. Total RNA was isolated from RBV r and RBV s Huh-7 cells as previously described (53) . Briefly, 1 ϫ 10 7 cells were collected, resuspended in a cell lysis buffer, and placed on ice for 5 min. Following centrifugation, sodium dodecyl sulfate (SDS) buffer was added, and samples were vortexed and then incubated with proteinase K. Nucleic acids were phenol-chloroform/isoamyl alcohol extracted and treated with a DNase solution, and samples were subjected to an additional phenol-chloroform/isoamyl alcohol extraction. The relative levels of ENT1, CNT3, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (as an internal control) RNAs were assessed using one-step reverse transcriptase PCR (RT-PCR) and the comparative threshold cycle (⌬⌬Ct) method (5) . Reactions were performed with an ABI 7500 sequence detection system (Applied Biosystems) and analyzed using ABI Sequence Detection 1.3 software. Reaction mixtures were plated in triplicate, each in a total volume of 25 l, and consisted of 50 ng of whole-cell RNA from RBV r and RBV (5), and the products were additionally verified by agarose gel electrophoresis. Analysis and methods used to determine the change (2 Ϫ⌬⌬Ct ) using the comparative (⌬⌬Ct) method have been previously described (5) . For immunoblot analysis, approximately 5 ϫ 10 5 Huh-7 and RBV r Huh-7 cells were collected via trypsinization and centrifugation, followed by three washes with ice-cold phosphate-buffered saline. Cell pellets were resuspended in a lysis buffer (10 mM Tris, 150 mM NaCl, 0.02% NaN 3 , 1% Na-deoxycholate, 1% Triton X-100, 0.1% SDS) containing 10 l/ml (each) of protease inhibitor cocktail (Sigma) and phosphatase inhibitor (Calbiochem). Lysates were centrifuged, and supernatants were removed and transferred to fresh tubes for protein concentration determination using a Bio-Rad protein assay. Twenty micrograms of protein was then separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Following primary (rabbit polyclonal immunoglobulin ENT1; Abgent) and secondary (donkey anti-rabbit immunoglobulin G-horseradish peroxidase; Jackson Immunoresearch) antibody probing, blots were developed using an ECL Plus chemiluminescence reagent (Amersham) according to the manufacturer's recommendations.
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Statistical analysis. Statistical significance was determined using independent two-sample Student's t test. Statistical significance was assigned to P values of less than 0.05.
RESULTS

RBV uptake and poliovirus growth in different cell lines.
To assess whether the amount of RBV uptake could impact viral replication, we measured RBV uptake in a variety of cell lines and measured the growth of a model RNA virus, poliovirus. Various cell lines were tested, including several liver cell lines (Huh-7, HepG2, and PH5CH8) and a Huh-7-based cell line previously shown to have reduced RBV uptake (Cured 4) (49). As expected, the RBV r Cured 4 cells took up significantly less RBV than all cell lines tested ( Fig. 1A ) (P Յ 0.005). Although the amount of RBV uptake varied between the remaining cell lines, Huh-7 cells took up significantly less than HeLa, HepG2, PH5CH8, and MCF7 cells (P Յ 0.01). We then determined whether differences in RBV uptake correlated with poliovirus growth efficiency in the presence of RBV. We chose poliovirus as a model RNA virus because RBV's antiviral mechanism for poliovirus, error catastrophe, has been established (8) . Since the mutagenic effects of RBV are cumulative and require several rounds of viral replication, an infection carried out over several days allows differences in viral growth to be observed (7, 8, 48, 49) . Therefore, we performed plaque assays with each of the cell lines in the absence or presence of 400 M RBV. Although the addition of RBV greatly inhibited viral growth in the majority of cell lines (Fig. 1B) , those with lower RBV uptake levels generally displayed enhanced viral growth, as measured by plaque size. The addition of RBV to the Cured 4 cell line had little effect on viral plaque size. Likewise, although a reduction in viral growth was observed for Huh-7 cells upon addition of RBV, the antiviral efficacy of the drug was reduced compared with cells having higher levels of uptake. These results suggest the possibility that low drug uptake facilitated enhanced viral growth in the presence of RBV.
Generation and characterization of new RBV r cell lines. The RBV r Cured 4 cell line generated previously had initially contained the HCV replicon, which was cured by IFN treatment (49). Consequently, it is possible that cellular resistance could have arisen due to virally induced changes in the cells. For this reason, we generated new RBV r versions of three cell lines, Huh-7, 293, and HeLa. RBV is toxic to a variety of cell lines at high micromolar concentrations (49, 71) . Therefore, we generated RBV r cell lines by passages in increasing doses of RBV as previously described ( Fig. 2A ) (49) . Once the cells were able to withstand high concentrations of RBV, they were tested for resistance alongside the parental RBV s cell lines. Both the RBV s and the RBV r cells were passaged for 10 days in medium containing 0 M, 100 M, or 400 M RBV. As shown in Fig. 2B , each of the RBV r cell lines survived treatment with either high-or lowdose RBV, whereas their RBV s counterparts could not. Importantly, all of the RBV r cells demonstrated significantly reduced RBV uptake (Fig. 2C ) (P Ͻ 0.01).
Our previous results suggested that reduced RBV uptake promotes increased viral growth (49) . Therefore, we performed poliovirus plaque assays to determine whether the new RBV r cell lines demonstrate increased permissivity for viral growth in the presence of RBV. Whereas RBV treatment severely limited viral growth in RBV s HeLa cells, it had little effect on viral growth in RBV r HeLa cells (Fig. 2D) . Poliovirus grown in RBV r Huh-7 cells also displayed an increased plaque size in the presence of RBV, although the viral growth difference between RBV s and RBV r Huh-7 cells was less than the viral growth difference observed for RBV s and RBV r HeLa cells. The minimal increase in plaque size in the RBV r Huh-7 cells in the presence of RBV could be due to the reduced uptake in these cells (Fig. 1) or to other host factors that enhance viral growth. Overall, these results indicate that a small reduction in RBV uptake (ϳ50% reduction in HeLa cells) (Fig. 2C) can have a major impact on poliovirus growth (Fig. 2D, HeLa cells) .
The role of nucleoside transporters in RBV uptake and resistance. RBV is transported into cells via nucleoside transporters. ENT1 is thought to be the primary RBV transporter (25) , although ENT2 and CNT2 may also transport RBV in human liver (20) . However, most previous studies measured RBV uptake in erythrocytes, and it is well known that nucleoside transporter expression varies in different tissues (20) . To determine which transporters are capable of importing RBV into liver cell lines, we transfected Huh-7 cells with several nucleoside transporter expression plasmids to determine which could increase RBV uptake. As shown in Fig. 3A , transfection of ENT1 and CNT3 expression plasmids increased RBV uptake. We next determined whether overexpression of ENT1 or CNT3 could rescue the RBV uptake defect in RBV r cells (Fig.  3B) . Transfection of the ENT1 or CNT3 expression plasmid r Huh-7 cells, nucleoside transporter overexpression was not able to fully restore the uptake defect (Fig. 3C) . While we cannot definitively rule out a role for ENT2, CNT1, and CNT2 in RBV transport based on this experiment, in later inhibition experiments, we confirm the role of ENT1 in RBV uptake (Fig. 4) . and ENT2-mediated transport can be differentiated based on levels of NBMPR sensitivity. ENT1 is NBMPR sensitive and is inhibited within the nanomolar range, while ENT2 is insensitive to nanomolar concentrations of NBMPR, with inhibition requiring concentrations within the high micromolar range (31, 67) . The RBV uptake assay was performed with RBV r and RBV s Huh-7 or HeLa cells in the presence or absence of NBMPR. For both Huh-7 and HeLa cells, NBMPR treatment reduced RBV uptake in RBV s cells threefold, to an amount comparable to the level of uptake of RBV r cells (Fig. 4A and  B ). Since treatment with 15 M NBMPR was not sufficient to completely inhibit ENT1 uptake, we repeated the experiment using a higher dose, 100 M NBMPR, which would completely block ENT1-mediated transport and likely ENT2-mediated transport as well. As anticipated, treatment of RBV s Huh-7 or HeLa cells with 100 M NBMPR reduced RBV uptake to match the low uptake of RBV r cells (Fig. 4A and B) . Although ENT3 or ENT4 are equilibrative transporters, they are not likely to be relevant for RBV uptake because ENT3 is localized in intracellular compartments, and ENT4 is a monoamine/ organic cation transporter (69) .
Because overexpression of CNT3 could also restore RBV uptake in RBV r cells, we performed the inhibition assay using the drug phloridzin, which is a broad concentrative transport inhibitor (22, 44, 61) . We observed no significant difference in the level of uptake in either the RBV r or RBV s Huh-7 or HeLa cells in the presence of phloridzin (Fig. 4C and D) . In order to confirm that the drug concentration used was sufficient to inhibit concentrative transport, Huh-7 cells were transfected with CNT3 and then subjected to the RBV uptake assay in the presence of phloridzin. We observed a dramatic decrease in the level of RBV uptake in the CNT3-transfected cells (Fig.  4E ), indicating that phloridzin was indeed capable of inhibiting concentrative transport. Taken together, these results suggest that endogenous uptake of RBV in Huh-7 and HeLa cells is primarily equilibrative, with the majority of uptake mediated by ENT1. Despite the fact that ENT1 overexpression could not completely restore RBV uptake in RBV r Huh-7 cells to the amount of uptake observed for RBV s Huh-7 cells, the robust inhibition of RBV uptake in RBV s Huh-7 cells by NBMPR (Fig. 4A) indicates that ENT1 is the likely RBV transporter in these cells. Additionally, our results indicate that for Huh-7 and HeLa cells, uptake is not mediated via concentrative transporters, since decreased uptake was not observed upon inhibition of concentrative transport.
Quantification of ENT1 expression in RBV s and RBV r cells. In some cases of acquired resistance to nucleoside analog drugs, a decrease in the level of nucleoside transporter RNA has been reported (15, 17, 59) . Therefore, we compared ENT1 and CNT3 RNA levels in RBV r and RBV s Huh-7 cells by using (Fig. 5A ). Although this small reduction in ENT1 RNA levels was statistically significant (P Ͻ 0.01), ENT1 protein levels were equivalent in RBV s and RBV r cells (Fig. 5B) . Therefore, ENT1 RNA and protein levels do not correlate with RBV uptake or resistance, suggesting that altered ENT1 localization or activity may contribute to resistance. These results highlight the importance of assessing the activity of nucleoside transporters, rather than RNA or protein levels.
Effect of nucleoside transporter activity on RBV-mediated viral growth inhibition. Our results indicated that the level of RBV uptake affects poliovirus growth ( Fig. 1 and Fig. 2D ), and inhibition of equilibrative transport reduced RBV uptake in RBV s cells (Fig. 4A and B) . Thus, we sought to determine whether the antiviral efficacy of RBV could be reduced in RBV s cells through equilibrative transport inhibition. Poliovirus plaque assays were performed in the absence or presence of RBV and in the absence or presence of NBMPR. As anticipated, the inhibition of equilibrative transport facilitated robust viral growth, despite the presence of RBV (Fig. 6) . We also performed the poliovirus plaque assays with the concentrative inhibitor phloridzin. We observed no difference in viral plaque sizes in the presence of phloridzin and RBV (data not shown). These results, in conjunction with our other data, indicate that endogenous ENT1 is responsible for RBV uptake in Huh-7 and HeLa cells and that ENT1-mediated RBV uptake facilitates RBV's antiviral effect in these cells.
Nucleoside uptake compensation mechanism in RBV r Huh-7 cells. Whereas ENT1 clearly plays a pivotal function in the uptake of RBV in Huh-7 and HeLa cells, we could not dismiss the possibility that ENT2 contributed to RBV uptake ( Fig. 4A and B) . The simplest method of differentiating ENT1-and ENT2-mediated uptake, other than NBMPR sensitivity, is through nucleobase transport. While ENT2 has the capacity to transport both nucleosides and nucleobases, ENT1 cannot transport nucleobases (24, 55, 64, 68) . Therefore, we monitored the uptake of [ 3 H]hypoxanthine, a nucleobase. In contrast to the low level of RBV uptake in RBV r Huh-7 cells, the level of hypoxanthine uptake in RBV r Huh-7 cells was increased almost threefold compared with that in RBV s Huh-7 Although not initially expected, these data provide evidence for a possible cellular compensation mechanism for reduced ENT1-mediated uptake. A deficiency in a broad transporter such as ENT1 would be expected to confer a cellular growth defect. Perhaps to compensate for the reduction in available nucleosides imported by ENT1, the activity of ENT2, another broad nucleoside transporter, increased. Interestingly, the level of hypoxanthine uptake was equivalent in RBV r and RBV s HeLa cells (Fig. 7B) , suggesting that the ENT2-mediated compensation mechanism may be unique to Huh-7 cells.
DISCUSSION
Only limited success has been achieved in treating those infected with HCV. Whereas much effort has been targeted toward understanding the mechanism of IFN and potential IFN resistance, relatively little effort has been directed toward understanding RBV. RBV has been shown to play an important role in the treatment response (14) , and higher RBV serum concentrations correlate with improved treatment outcome (26, 34) . However, we still do not understand how RBV works synergistically with IFN to improve SVR rates or whether resistance to RBV develops in patients.
Our goal in this study was to gain a better understanding of potential RBV resistance mechanisms by using a cell culture system. We began by examining the levels of RBV uptake among several cell lines and found it to vary. We next ascertained whether RBV uptake level influenced antiviral efficacy by performing poliovirus plaque assays. It is known that poliovirus is sensitive to RBV at high concentrations, such as 400 M. Additionally, the antiviral mechanism of RBV, increasing the error rate to the point of error catastrophe (8) , is well established for poliovirus. We observed an inverse relationship, where decreased RBV uptake facilitated increased viral growth in the presence of RBV (Fig. 1B) . Importantly, a high dose of RBV was used in this study and is required to observe effects on poliovirus growth (7, 8, 48, 49) . Although the concentration of RBV in plasma is significantly lower (ϳ10 M), RBV may accumulate to higher concentrations in the liver (18) .
Since the focus of our work was to understand potential host-mediated RBV resistance, we generated new RBV r cell lines using cells that had not previously contained the HCV replicon (49) . Resistance was achieved in all three cell lines, and the RBV r phenotype was stable, with cells maintaining their resistance despite months of culture in media lacking RBV (data not shown). When tested for RBV uptake, all RBV r cell lines demonstrated significantly reduced uptake compared to their RBV s counterparts (Fig. 2C) . Upon performing poliovirus plaque assays in these new RBV r cell lines, we found that RBV resistance also facilitated increased poliovirus growth in the presence of RBV (Fig. 2D) . These results indicate that a reduction in RBV uptake can promote increased poliovirus growth.
As RBV is imported by nucleoside transporters, we assessed the contribution of several nucleoside transporters to RBV resistance in our cell lines. After surveying several transporters, we found that overexpression of ENT1 and CNT3 increased RBV uptake. Although ENT1 is widely accepted as the primary RBV transporter, there have been additional reports suggesting that other transporters can import RBV (13, 20, 45, 66) ; indeed, our findings confirm CNT3-mediated RBV uptake. Additionally, we determined whether overexpression of ENT1 or CNT3 could restore the uptake defect in RBV r cells. We found that in the majority of RBV r cells, overexpression of ENT1 or CNT3 could restore RBV uptake (Fig. 3B) . While transfection of ENT1 and CNT3 significantly increased uptake in RBV s Huh-7, 293, and HeLa cells, it could completely restore the uptake defect in only RBV r 293 and HeLa cells. The fact that uptake could not be completely restored in RBV r Huh-7 cells (Fig. 3C) suggests other factors could interfere with RBV uptake in RBV r Huh-7 cells, perhaps by limiting nucleoside transporter activity or localization. However, RBV uptake could be completely restored in ENT1-or CNT3-transfected RBV r Huh-7.5 cells, a liver cell line derived from Huh-7 cells (data not shown). These results indicate that multiple pathways can lead to RBV resistance, even in transformed cells of the same lineage, such as Huh-7 and Huh-7.5 cells. We hypothesize that ENT1 protein is mislocalized in RBV r Huh-7 cells. There is evidence that localization of ENT1 and other transporters can change from the plasma membrane to intracellular membrane compartments in response to various stimuli, including adaptation to two-dimensional tissue culture (20) (see below). Similarly, the expression and activity of transporters can change in response to transformation (11) . Therefore, although our results with Huh-7 cells may or may not apply to liver cells in vivo, they provide a foundation for future studies of the role of nucleoside transporters in host-based RBV resistance and antiviral efficacy.
Whereas ENT1 is ubiquitously expressed, the expression of CNT3 is normally restricted to a few tissues, with low expression levels reported for the liver (4, 21) . The most common method of determining endogenous transport activity is through uptake assays performed in the presence of specific inhibitors. Experiments performed using NBMPR (an ENT1 inhibitor) and phloridzin (a broad concentrative nucleoside transport inhibitor) indicated that RBV uptake occurs primarily through ENT1 (Fig. 4A and B) . While CNT3 was capable of increasing RBV uptake into the cells upon transfection (Fig.  3B) , CNT3 expression was undetectable in nontransfected Huh-7 cells as measured by real-time RT-PCR (data not shown). These data suggest that ENT1 is the RBV transporter in the Huh-7 hepatoma cell line.
Host-based resistance to treatment with nucleoside analogs is not uncommon in cancer patients, and numerous studies linking nucleoside analog drug resistance to decreased nucleoside transporter expression have been reported (15, 17, 59) . Accordingly, we quantified ENT1 RNA levels in the RBV r and RBV s Huh-7 cells, and found only slightly reduced ENT1 expression in RBV r cells (Fig. 5 ). An immunoblot analysis indicated that ENT1 protein levels are equivalent in RBV r and RBV s cells (Fig. 5B) , providing support for the idea that ENT1 activity or protein localization is altered in RBV r cells. Perhaps some modification occurred that altered the activity of ENT1, or altered the plasma membrane localization of ENT1, thus conferring the RBV r phenotype. While much remains to be understood regarding regulation, localization, and activity of nucleoside transporters, there is a precedent for localization of transporters in internal cell compartments (20, 32, 38, 41, 51 ). Altered ENT1 localization would account for the similar ENT1 RNA and protein levels found in RBV r and RBV s cells. It is also possible that RBV resistance is conferred by altered RBV processing pathways, such as reduced phosphorylation or increased degradation. There have been several cases in which resistance correlates with either a decrease in the level of activating kinases required for nucleoside phosphorylation or an increase in the level of 5Ј nucleotidases capable of dephosphorylating nucleoside analogs (16, 17, 38) . However, the facts that uptake of RBV was reduced in RBV r cell lines, that no difference was found in the levels of export of RBV (data not shown), and that inhibition of ENT activity mimicked the RBV r cell phenotype suggest that RBV resistance is due to altered ENT1 activity and not phosphorylation, degradation, or efflux effects.
After establishing that the level of RBV uptake affects viral growth and that endogenous ENT1 was primarily responsible for uptake, our next step was to demonstrate the antiviral impact of altered uptake. Our results illustrated two key points. First, by blocking equilibrative transport, uptake in the RBV s cells mirrored that in the RBV r cells. Second, inhibition of RBV uptake reduced antiviral efficacy, with poliovirus growth in the RBV s cells mirroring that in the RBV r cells in the presence of nucleoside transport inhibitor (Fig. 6) . Overall, our results indicate a role for ENT1-mediated RBV transport in the uptake of RBV and suggest that a reduction in ENT1 activity may play a role in the acquisition of resistance.
The idea that host-based nucleoside uptake defects can affect antiviral efficacy may have clinical relevance. Similar to cancer patients undergoing chemotherapy, chronically infected hepatitis C patients undergo harsh, toxic, long-term treatments. The standard of care for treating HCV infection includes a combination of pegylated IFN-␣ and RBV for 24 to 48 weeks. Treatment with IFN alone can have side effects, but RBV is also a toxic drug capable of inducing hemolytic anemia. As with long-term exposure to cytotoxic nucleoside analogs in chemotherapy, it is plausible that host-based drug resistance could occur in response to RBV treatment. Constant exposure to RBV toxicity could trigger reduced transporter activity. Liver cells, like many others, are capable of de novo nucleoside synthesis. Additionally, the liver is considered the main site of nucleoside synthesis, providing a reservoir of nucleosides for other cells in the body which lack de novo synthesis (31) . It is likely that any disadvantage conferred by downregulation of a broad transporter such as ENT1 would be outweighed by the advantage of hepatocyte survival.
Our work also suggests that for RBV r Huh-7 cells, a compensation mechanism upregulates the activity of an alternate transporter, ENT2 (Fig. 7A) . Furthermore, these results provide additional evidence, indirectly, that ENT1 is indeed the primary RBV nucleoside transporter in Huh-7 cells. We surmise that upregulation of an alternate transporter offsets the disadvantage caused by downregulation of ENT1 activity. Therefore, we suggest that ENT1 downregulation is primarily responsible for RBV resistance and that Huh-7 cells compensate for reduced nucleoside uptake by upregulation of the ENT2 transporter. RBV r HeLa cells did not exhibit this ENT2-mediated compensation mechanism (Fig. 7B) . Interestingly, RBV r HeLa cells grow significantly slower than RBV r Huh-7 cells (data not shown).
It is possible that nucleoside transporter activity could aid in the prediction of treatment success. Perhaps elevated RBV uptake correlates with overall treatment success. Higher RBV serum concentrations have been associated with SVR (26, 34) . SVR rates of up to 90% have been achieved by using extremely high doses of RBV (35) , albeit with increased toxicity. We are currently measuring RBV uptake in HCV patient samples and determining the effect of the RBV uptake level on the HCV treatment response and HCV replication. If RBV uptake can affect the treatment response, either through natural transport differences in the population or through acquired resistance, then tailored treatment regimens may enhance the treatment response.
